Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00362674
Status:
COMPLETED
Last Update Posted:
2017-02-01
First Post:
2006-08-08
Brief Title:
Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301302 or 303 Trial
Sponsor:
Bukwang Pharmaceutical
Organization:
Bukwang Pharmaceutical
Study Overview
Official Title:
An Open-label Observation Study to Evaluate the Durability of Antiviral Activity in Chronic Hepatitis B Patients Who Showed Complete Response in L-FMAU-301L-FMAU-302 or L-FMAU-303 Trial
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the durability of antiviral activity in chronic hepatitis B patients who showed complete response in L-FMAU-301L-FMAU-302 or L-FMAU-303 trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None